Nanoparticle Distributed Intravenous Enzyme Replacement Therapy (NanoDIVERT)

纳米颗粒分布式静脉酶替代疗法(NanoDIVERT)

基本信息

  • 批准号:
    10723846
  • 负责人:
  • 金额:
    $ 40.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT ABSTRACT Enzyme replacement therapy (ERT) has been successful in ameliorating symptoms of patients with non- neuropathic lysosomal storage disorders (LSDs), making it a viable therapeutic approach for these rare, orphan genetic diseases. Essentially, patients receive intravenous (IV) infusions of endogenous enzymes that are either present at low concentration, missing entirely, or misfolded, and therefore dysfunctional due to their genetic disease. Despite its promise in the clinic, ERT cannot be used to treat 50-70% of LSDs with central nervous system manifestation due to the blood-brain barrier (BBB) which prevents the passage of recombinant enzymes from the blood into the brain. One of these diseases and the focus of this proposal, GM1 gangliosidosis, arises from variants in GLB1 that leads to decreased production of lysosomal β-galactosidase (βgal). Its most common form results in mortality between the ages of 2 and 4. Recently, our laboratory has created nanoparticle vesicles, called polymersomes, capable of encapsulating and delivering βgal to lysosomes of GM1-affected cells, where the delivered enzyme maintains its activity. Preliminary data in a feline model of GM1 gangliosidosis shows that with the addition of an apolipoprotein on the surface, polymersomes transport active βgal across the BBB within 48 hours after an intravenous forelimb injection. This approach to treatment, titled nanoparticle distributed IV ERT (NanoDIVERT), can potentially extend ERT into the central nervous system, which could impact not only GM1 gangliosidosis but also other orphan neuropathic LSDs. To further test the applicability of the nanoparticle- mediated approach to IV ERT, we will optimize in vivo performance. Specifically, we aim to increase delivery to the brain and determine the most appropriate dosing for therapeutic effects. We aim to initially optimize NanoDIVERT in a murine model of GM1 gangliosidosis, for testing in greater animal numbers, before scaling up to large animal models. The outcome of these studies could enable the development of a clinically relevant ERT for GM1 gangliosidosis and other neuropathic LSDs for the first time.
项目摘要 酶替代疗法(ERT)已成功地改善非霍奇金淋巴瘤患者的症状。 神经病理性溶酶体储存障碍(LSD),使其成为这些罕见的孤儿的可行治疗方法 遗传病。基本上,患者接受静脉(IV)输注内源性酶,这些酶可以是 以低浓度存在、完全缺失或错误折叠,因此由于它们的基因而功能失调 疾病。尽管ERT在临床上很有希望,但它不能用于治疗50%-70%的LSD合并中枢神经系统疾病 由于血脑屏障(BBB)阻止重组酶通过而导致的系统表现 从血液进入大脑。这些疾病中的一种,也是本提案的焦点,GM1神经节苷脂沉积症 导致溶酶体β-半乳糖苷酶(βGAL)产生减少的GLB1变异体。它是最常见的 形式会导致2到4岁的儿童死亡。最近,我们的实验室创造了纳米颗粒囊泡, 称为聚合体,能够包裹βGal并将其运送到受GM1影响的细胞的溶酶体中,其中 交付的酶保持其活性。GM1神经节苷脂沉积症猫科动物模型的初步数据显示 随着载脂蛋白在表面的增加,多聚体将活性β半乳糖跨血脑屏障运送到 静脉注射前肢后48小时。这种治疗方法被称为纳米粒子分布IV ERT(NanoDIVERT),可能会将ERT扩展到中枢神经系统,这不仅会影响 GM1神经节苷脂沉着症,也是其他孤儿神经性LSD。为了进一步测试纳米颗粒的适用性- 将介导性方法应用于IVERT,我们将优化体内性能。具体地说,我们的目标是将交付增加到 并确定最合适的治疗效果剂量。我们的目标是初步优化 用于GM1神经节苷脂增多症小鼠模型的NanoDIVERT,用于在扩大规模之前在更多动物中进行测试 到大型动物模型。这些研究的结果可能使临床相关ERT的发展成为可能 首次用于GM1神经节苷脂沉着症和其他神经性LSD。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Marie Larsen其他文献

Jessica Marie Larsen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 40.46万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 40.46万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 40.46万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 40.46万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 40.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 40.46万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 40.46万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 40.46万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 40.46万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 40.46万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了